Literature DB >> 17202178

Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases.

N Costedoat-Chalumeau1, J-S Hulot, Z Amoura, G Leroux, P Lechat, C Funck-Brentano, J-C Piette.   

Abstract

OBJECTIVE: The antimalarial agents chloroquine (CQ) and hydroxychloroquine (HCQ) are used in long-term treatment of connective tissue diseases (CTDs). A high incidence of heart conduction disorders, including bundle-branch block and incomplete or complete atrioventricular block, has been observed among patients treated with CQ. Since no data were available for HCQ, we studied electrocardiograms (ECGs) in 85 unselected patients with CTD treated with HCQ as the sole antimalarial.
METHODS: Eighty-five unselected out-patients treated with HCQ for a minimum of 1 yr, and without established cardiac diseases had standard 12-lead ECGs.
RESULTS: Two incomplete right bundle-branch blocks and one left bundle-branch block were observed. No atrioventricular block was observed. The mean PR interval was 137 +/- 20 ms (range 99-188). The mean QTc interval was 410 ms (range 349-464). The mean heart rate was 73 beats/min (range 53-102).
CONCLUSION: PR interval, QTc interval and heart rate were not different from normal values. The rate of heart conduction disorders was similar to what is expected in the general population, and contrasted with prior results in CQ-treated patients. Our results add further evidence on the safety of HCQ compared with CQ.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17202178     DOI: 10.1093/rheumatology/kel402

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  32 in total

Review 1.  The role of antimalarial agents in the treatment of SLE and lupus nephritis.

Authors:  Senq-J Lee; Earl Silverman; Joanne M Bargman
Journal:  Nat Rev Nephrol       Date:  2011-10-18       Impact factor: 28.314

2.  Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature.

Authors:  Clotilde Chatre; François Roubille; Hélène Vernhet; Christian Jorgensen; Yves-Marie Pers
Journal:  Drug Saf       Date:  2018-10       Impact factor: 5.606

3.  Hydroxychloroquine as a glucose lowering drug.

Authors:  Elizabeth Martha Winter; Anita Schrander-van der Meer; Carmen Eustatia-Rutten; Martien Janssen
Journal:  BMJ Case Rep       Date:  2011-10-28

4.  Electrophysiological and Proarrhythmic Effects of Hydroxychloroquine Challenge in Guinea-Pig Hearts.

Authors:  Gongxin Wang; Chieh-Ju Lu; Andrew W Trafford; Xiaohui Tian; Hannali M Flores; Piotr Maj; Kevin Zhang; Yanhong Niu; Luxi Wang; Yimei Du; Xinying Ji; Yanfang Xu; Lin Wu; Dan Li; Neil Herring; David Paterson; Christopher L-H Huang; Henggui Zhang; Ming Lei; Guoliang Hao
Journal:  ACS Pharmacol Transl Sci       Date:  2021-08-30

Review 5.  Revisiting cardiac safety of hydroxychloroquine in rheumatological diseases during COVID-19 era: Facts and myths.

Authors:  Shivraj Padiyar; Debashish Danda
Journal:  Eur J Rheumatol       Date:  2020-10-08

6.  Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Robert P Baughman; Keith C Meyer; Ian Nathanson; Luis Angel; Sangeeta M Bhorade; Kevin M Chan; Daniel Culver; Christopher G Harrod; Mary S Hayney; Kristen B Highland; Andrew H Limper; Herbert Patrick; Charlie Strange; Timothy Whelan
Journal:  Chest       Date:  2012-11       Impact factor: 9.410

7.  Lack of efficacy of hydroxychloroquine and azithromycin in patients hospitalized for COVID-19 pneumonia: A retrospective study.

Authors:  Anis Saib; Walid Amara; Pascal Wang; Simon Cattan; Azeddine Dellal; Kais Regaieg; Stephane Nahon; Olivier Nallet; Lee S Nguyen
Journal:  PLoS One       Date:  2021-06-09       Impact factor: 3.240

8.  Assessment of hydroxychloroquine maculopathy after cessation of treatment: an optical coherence tomography and multifocal electroretinography study.

Authors:  Marilita M Moschos; Eirini Nitoda; Irini P Chatziralli; Zisis Gatzioufas; Chryssanthi Koutsandrea; George Kitsos
Journal:  Drug Des Devel Ther       Date:  2015-06-11       Impact factor: 4.162

9.  Hydroxychloroquine Use Is Not Associated With QTc Length in a Large Cohort of SLE and RA Patients.

Authors:  Elizabeth Park; Jon T Giles; Thania Perez-Recio; Paloma Pina; Christopher Depender; Yevgeniya Gartshteyn; Anca Askanase; Joan Bathon; Laura Geraldino-Pardilla
Journal:  Res Sq       Date:  2021-06-29

10.  The effect of hydroxychloroquine on glucose control and insulin resistance in the prediabetes condition.

Authors:  Fahimeh Sheikhbahaie; Masoud Amini; Mojgan Gharipour; Ashraf Aminoroaya; Nader Taheri
Journal:  Adv Biomed Res       Date:  2016-08-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.